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bjectives Our aim was to test whether serum levels of matrix metalloproteinase (MMP)-2 and -9
re associated with the development of in-stent restenosis (ISR) after implantation of drug-eluting
tents (DES).
ackground With the introduction of DES coronary ISR could be reduced dramatically. However, it
till plays a signiﬁcant role, particularly after treatment of multiple, complex lesions.
ethods We studied 85 patients who were treated with 159 DES. Blood samples for measurement
f MMP-2 and -9 antigen and activity were taken directly before and 24 h after percutaneous coro-
ary intervention (PCI). Restenosis was evaluated at 6 to 8 months by coronary angiography.
esults During the follow-up period, 2 patients (2.4%) died of cardiovascular causes, and 12 pa-
ients developed angiographic ISR. Patients with ISR showed signiﬁcantly higher serum activity of
MP-9 at baseline (p  0.017) and of MMP-2 (p  0.0001) and MMP-9 (p  0.0001) after the proce-
ure. The PCI increased serum activity of MMP-2 (p  0.005) and MMP-9 (p  0.008) only in pa-
ients with ISR. The restenosis rates of patients in the highest quartile of MMP-2 after and MMP-9
efore and after PCI were 40.0%, 38.9%, and 42.9% compared with 6.3%, 7.7%, and 4.0% in the
ower quartiles, respectively. This was independent of clinical and procedural characteristics.
onclusions Elevated serum activities of MMP-2 and -9 are associated with dramatically increased
estenosis rates after PCI with implantation of DES. Determination of MMP levels might be useful for
dentiﬁcation of patients who are at high risk for ISR despite implantation of DES. (J Am Coll
ardiol Intv 2010;3:90–7) © 2010 by the American College of Cardiology Foundation
rom the *Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; and the †Third Department of
edicine, Wilhelminen Hospital, Vienna, Austria. This work was supported by the Ludwig Boltzmann Foundation for
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91espite possible safety issues, the implantation of drug-
luting stents (DES) is the most widely used method for
oronary artery revascularization, and it has become the
ost powerful means to treat coronary artery stenosis. But
verall in-stent restenosis (ISR) still remains a limitation for
he long-term clinical outcome. A recently published article
1) suggests that in a real-world population the angiographic
estenosis rate of DES could be up to 18%, particularly after
reatment of multiple, complex lesions. Thus the question
rises of whether known risk factors for ISR in bare-metal
tents (BMS) are also playing a role in DES.
It is known that coronary interventions induce an
nflammatory response by arterial wall damage, release of
nflammatory and chemoattractant factors resulting in
eukocyte and platelet activation (2). Migration and
roliferation of neointimal smooth muscle cells together
ith the deposition of extracellular matrix might lead to
he development of ISR. Previous studies have shown
hat mechanical injury (3–7) induces expression of matrix
etalloproteinases (MMP) and increases gelatinase activity
3,8). Gelatinase A (MMP-2) and Gelatinase B (MMP-9)
odulate matrix degradation and smooth muscle cell mi-
ration and might thereby play a role in the pathogenesis of
estenosis. Increased MMP-9 serum levels were significantly
ssociated with increased neointima formation (9), and serum
evels of MMP-2 and -9 were found to be related with
estenosis in BMS (10–12). However, not much is known
bout the role of MMPs in the pathogenesis of restenosis after
mplantation of paclitaxel-eluting stents (PES) (Taxus, Boston
cientific Corp., Natick, Massachusetts) and sirolimus-eluting
tents (SES) (Cypher, Cordis Corp., Miami Lake, Florida),
ecause these substances exert direct antimigratory and anti-
nflammatory effects (13,14). Therefore, our aim was to eval-
ate the role of MMP-2 and -9 in the development of ISR
fter implantation of PES and SES.
ethods
atients. Blood samples were taken prospectively from 544
onsecutive patients with suspected stable coronary artery
isease who were scheduled for elective PCI (Fig. 1). The
CIs were performed according to standard techniques by
xperienced interventionalists only. The type, number, length,
nd size of the stents implanted were left to the discretion of
he interventionalist. All patients with DES only (n  107)
ere asked to participate in this study, and we performed
e-angiography in all 85 patients who gave their informed
onsent for follow-up angiography. The Taxus stents (PES)
ere implanted in 63 patients (75%); Cypher stents (SES)
ere used in 22 patients (25%). The study was approved by the
nstitutional ethics committee for human subjects. Patients
ith acute coronary syndrome within 3 months before angio-
lasty were excluded. Exclusion criteria included also concur- oent severe illness (such as cancer, hepatic or renal disease, or
hronic infections), PCI for restenosis, and unsuccessful pro-
edure (i.e., 50% diameter stenosis after the intervention).
spirin and unfractionated heparin were administered per
tandard practice. Clopidogrel therapy was started either on
he day before angiography or immediately after stent implan-
ation with 4 tablets (300 mg). After the procedure, patients
ere maintained on aspirin 100 mg indefinitely, and clopi-
ogrel 75 mg at least until follow-up angiography. Other
edications such as beta-blockers, statins, and angiotensin-
onverting-enzyme inhibitors were given as appropriate. After
nrollment, patients remained in the hospital for at least 48 h.
lood samples. Two blood samples were taken under fasting
onditions directly before PCI and 24 h after PCI. Therefore
enous blood was drawn from the antecubital vein with
inimal tourniquet pressure into serum separator tubes. Sam-
les were allowed to clot for 30 min before centrifugation (4°C;
,000 g for 15 min) and stored at 70°C until use.
aboratory measurements. The MMP-2 and -9 antigens
ere measured with specific
nzyme-linked immunosorbent
ssays (Amersham, GE Health-
are Bio-Sciences AB, Uppsala,
weden). The MMP-2 and -9
ctivities have been determined
ith specific activity assays
Amersham).
ngiographic deﬁnitions. The
odified American College of
ardiology/American Heart As-
ociation grading system (type A,
1, B2, and C) was used to char-
cterize lesion morphology. The
ff-line quantitative coronary an-
iographic analysis was performed
ith an automated edge-detection system (QCA-CMS Ver-
ion 6.0, Medis, Medical Imaging Systems, Leiden, the Neth-
rlands). The contrast-filled, nontapered catheter tip was used
or calibration. The reference diameter was measured by
nterpolation. Minimal lumen diameter (before and after PCI)
nd diameter stenosis (before and after PCI) were measured
ithin the stent and within the 5-mm proximal and distal
dges of the stent. Furthermore, we measured vessel size, lesion
ength, and length of stented segment. All analyses were
erformed by the same investigator that was blinded to all
aboratory results.
nd points. The primary end point of the study was angio-
raphic restenosis (diameter stenosis of at least 50% on the
asis of in-segment analysis) at follow-up angiography, which
as performed at 6 to 8 months’ follow-up or earlier if
linically indicated. The secondary end points were in-stent
ate lumen loss and the need for target lesion revascularization
ue to restenosis in the presence of symptoms or objective signs
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MMP  matrix
metalloproteinase
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)f ischemia during the follow-up.
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92tatistical analysis. Sample size calculation was based on the
ypothesis that MMP-2 and/or -9 activity before PCI show a
ifference of at least 50% in patients with and without ISR.
alculation of sample size revealed that, with an expected “real
orld” restenosis rate of 10%, 40 patients were needed to
etect a 50% difference of MMP-2 activity, and 80 patients
ere needed to detect a 50% difference in MMP-9 activity
efore PCI between patients with and without ISR with a
ower of 80% and significance level (2-tailed) of 0.05 (15). For
ll additional comparisons (MMP antigen levels, post-
rocedure MMP levels, and increase of MMP levels upon
CI), we used the method according to Bonferroni-Holm to
ccount for multiple testing. In patients with multiple lesion
nterventions, only the lesion with the highest late lumen loss
as included. Continuous variables are expressed as mean 
D. Demographic data of patients with and without restenosis
ere compared by the unpaired Student t test. Categorical
ariables are summarized as counts and percentages and were
ompared by the chi-square or by Fisher exact test. Serum
evels of MMPs were compared by Mann-Whitney U test, and
ifferences before and after PCI were determined by the
ilcoxon signed rank test for paired samples. Pearson’s cor-
elation was used to correlate MMP levels with late lumen loss
fter log10-transformation. Because a multivariable analysis
as not feasible with only 12 ISR events, we adjusted only for
hat variable that was identified as the strongest confounding
ariable. As strongest confounder we selected that variable that
mplied the strongest modification of the odds ratio of the
544 pts. scheduled
angiography for suspe
meeting all inclus
184 pts. with
coronary interventions
107 pts. drug-
eluting stents
30 pts. bare 
metal stents
23 pts. PTC
only
85 consent
for re-angiograph
22  no consent
for re-aniography
71 no
restenosis
12 in-stent
restenosis
Figure 1. Study Flow Chart
Of 544 consecutive patients, 184 underwent percutaneous coronary interventio
follow-up angiography. CABG  coronary artery bypass graft; CAD  coronaryespective MMP level toward 1 among all bivariable models. A aalue of p  0.05 (2-tailed) was considered statistically signif-
cant. All statistical analyses were performed with the statistical
oftware package SPSS version 11.0 (SPSS, Inc., Chicago,
llinois). The authors had full access to the data and take
esponsibility for its integrity. All authors have read and agree
o the manuscript as written.
esults
hirty SES (Cypher) were used in 22 patients (25%), and 129
ES (Taxus) were implanted in 63 patients (75%). During
ollow-up 2 patients (2.4%) died of cardiovascular causes
ithout evidence of stent thrombosis, and ISR occurred in 12
atients (14.5% of patients, 7.6% of stents). Target lesion
evascularization was performed in all 12 patients. Patients
ith and without restenosis at follow-up angiography showed
o significant differences in baseline clinical characteristics,
ardiovascular risk factors, and medication (Table 1). There
ere also no significant differences in angiographic character-
stics; however, the mean stent diameter was lower and the
umber of stents tended to be higher in patients with restenosis
Table 2).
Except MMP-2 antigen levels, which were higher in dia-
etic patients (799.58  276.34 ng/ml vs. 667.82  204.95
g/ml; p  0.038) and increased with age (R  0.258; p 
.018), MMP-2 and -9 antigen and activity levels at baseline
ere not associated with cardiovascular risk factors and demo-
raphic data, respectively. The MMP levels were also not
ronary
stable CAD
riteria
360 pts. w/o
nary interventions
68 w/o significant
coronary stenosis
31 scheduled
for CABG
261 conservative
managment
4 procedures
ot successful
2
eaths
107 patients with drug-eluting stents, 85 gave their informed consent for
disease; PTCA  percutaneous transluminal coronary angioplasty.for co
cted
ion c
coro
A 2
n
y
d
n. Ofssociated with number of diseased vessel, lesion type, and size.
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93erum levels of MMP-2 and -9 at baseline in patients with and
ithout restenosis. Patients with ISR at follow-up showed
ignificantly higher MMP-9 activity levels before PCI
31.53  16.9 ng/ml vs. 21.16  10.87 ng/ml; p 
.017). The MMP-2 activity levels as well as MMP-2
nd MMP-9 antigen levels were not different in patients
ith and without ISR at baseline (Table 3).
erum levels of MMP-2 and -9 24 h after PCI in patients with and
ithout restenosis. In contrast to patients without ISR, in
atients with ISR at follow-up angiography, the PCI proce-
ure induced a significant increase of MMP-2 activity (p 
.0001) and MMP-2 antigen (p  0.005) as well as MMP-9
ctivity levels (p  0.0001) (Table 3). Twenty-four hours
fter PCI, MMP-2 activity levels (44.20  10.70 ng/ml vs.
9.23  8.64 ng/ml, p  0.001) as well as MMP-9 activity
evels (54.25  28.77 ng/ml vs. 24.75  12.38 ng/ml, p 
.001) were significantly higher in patients with ISR com-
ared to patients without ISR (Fig. 2).
MP activity predicts risk of restenosis after PCI. The restenosis
ates of patients in the highest quartile of MMP-2 activity after
CI and MMP-9 activity before and after PCI were 40.0%,
8.9%, and 42.9% compared with a mean restenosis rate of
.3%, 7.7%, and 4.0% in the 3 lower quartiles, respectively (Fig.
). Whereas MMP-2 activity at baseline was no predictor for
SR, MMP-2 activity after PCI and MMP-9 activity before
nd after PCI predicted ISR independently from clinical,
ngiographic, and procedural risk factors as assessed by logistic
Table 1. Baseline Characteristics of Patients With and
Without Restenosis
Total
(n  85)
Restenosis
(n  12)
No Restenosis
(n  73) p Value
Age (yrs) 64 10.5 66.8 7.3 63.6 10.9 0.33
Sex (male) 66 (79.5) 9 (75) 57 (80.3) 0.70
Hypertension 63 (75.9) 7 (58.3) 56 (78.9) 0.12
Diabetes 25 (30.1) 3 (25) 22 (31) 0.48
Family history of
coronary artery
disease
46 (55.4) 7 (58.3) 39 (54.9) 0.54
Smoker 28 (33.7) 4 (33.3) 24 (33.8) 1.00
BMI (kg/m2) 27.9 3.7 26.6 3.6 28.1 3.7 0.20
Triglycerides (mg/dl) 174.6 99.3 158.9 70.2 177.2 103.5 0.50
TC (mg/dl) 189.2 43.5 186.4 26.9 189.7 45.8 0.81
HbA1c (%) 6.0 0.7 6.1 0.6 6.0 0.8 0.83
CRP (mg/dl) 0.29 0.28 0.28 0.28 0.29 0.28 0.87
Leukocytes (109/l) 6.7 1.5 6.5 1.8 6.7 1.4 0.60
ACE inhibitor 35 (42.2) 7 (58.3) 28 (39.4) 0.34
ARB 10 (12) 1 (8.3) 9 (12.7) 1.00
Beta-blocker 44 (53) 8 (66.7) 36 (50.7) 0.36
Statin 64 (77.1) 9 (75) 55 (77.5) 1.00
Values are given as mean SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
index; CRPC-reactive protein; HbA1c glycosylated hemoglobin; TC total cholesterol.egression model (Table 4).orrelation of late lumen loss with MMP activity. In contrast
o MMP-2 (R  0.03, p  0.81) and MMP-9 (R  0.14,
 0.21) activity at baseline, MMP-2 activity (R  0.34,
 0.005) and MMP-9 activity after the procedure (R 
.53, p  0.000001) were correlated with late lumen loss at
ollow-up (Fig. 4). Similar results were obtained when
atients were stratified according to stent type. The
MP-9 activity showed a significant correlation with late
umen loss of PES (R  0.52, p  0.00005) and SES (R 
.59, p  0.005), respectively. The MMP-2 activity corre-
ated significantly with late lumen loss of PES (R  0.36,
 0.005) but not of SES (R  0.19, p  NS).
iscussion
he present study, which prospectively investigated angio-
raphic outcome after implantation of DES, showed that
levated baseline serum activity of MMP-9 and increased
ost-procedural serum activities of MMP-2 and -9 were
ighly associated with the development of ISR. Multiple
ogistic regression demonstrated that MMP-2 and -9 activ-
ty levels independently predicted the occurrence of reste-
osis after implantation of DES.
Previous studies in patients with BMS suggested that
ntigen levels of MMP-2 and -9 might predict occurrence of
estenosis (10,11), and it has been demonstrated retrospectively
hat patients with ISR in BMS showed increased MMP-9
Table 2. Angiographic and Procedural Characteristics of Patients With
and Without Restenosis
Restenosis
(n  12)
No Restenosis
(n  73) p Value
Angiography
CAD extent (1VD/2VD/3VD) 3/6/3 24/28/19 0.77
Target vessel
LAD 7 (58.3) 41 (57.7) 0.69
LCx 1 (8.3) 12 (16.9)
RCA 4 (33.3) 18 (25.4)
Lesion type (A/B/C) 1/9/2 17/47/7 0.43
Vessel size (mm) 3.23 0.39 3.26 0.37 0.79
MLD (mm) 0.67 0.21 0.67 0.23 0.99
DS (%) 78.7 7.04 80.03 7.14 0.55
Intervention
Number of stents/procedure 2.33 1.37 1.79 0.92 0.08
Number of stents/vessel 1.58 0.8 1.29 0.57 0.13
Type of stent
Taxus 11 (91.7) 49 (69) 0.17
Cypher 1 (8.3) 22 (31)
Stent diameter (mm) 2.77 0.27 2.97 0.33 0.03
Length of stented segment (mm) 22.42 4.58 20.79 6.38 0.40
MLD after procedure (mm) 2.63 0.41 2.66 0.35 0.78
Values are given as n or mean SD.
CAD  coronary artery disease; DS  diameter stenosis; LAD  left anterior descending
coronary artery; LCx  left circumflex coronary artery; MLD  minimal lumen diameter; RCA right coronary artery; 1VD/2VD/3VD single-/double-/triple-vessel disease.
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94ctivity 1 year after the initial stent placement (12). Interest-
ngly, in accordance with these studies and despite the anti-
nflammatory and antimigratory effects of sirolimus and pacli-
axel (13,14,16), this study provides evidence that gelatinase
erum activity might also play a crucial role in the development
f ISR after implantation of DES.
Table 3. MMP Serum Levels in Patients With and Wi
Restenosis
(n  12)
Before procedure
MMP-2 antigen (ng/ml) 645.28 166.23
MMP-2 activity (ng/ml) 27.68 6.36
MMP-9 antigen (ng/ml) 855.83 377.44
MMP-9 activity (ng/ml) 31.53 16.90
After procedure
MMP-2 antigen (ng/ml) 1,080.93 615.17
MMP-2 activity (ng/ml) 44.20 10.70
MMP-9 antigen (ng/ml) 1,124.31 396.73
MMP-9 activity (ng/ml) 54.25 28.77
PCI-induced change
MMP-2 antigen (ng/ml) 435.66 618.78
MMP-2 activity (ng/ml) 16.52 11.12
MMP-9 antigen (ng/ml) 268.48 481.49
MMP-9 activity (ng/ml) 22.72 25.40
Values are given as mean SD. *The p values corrected according to
primary hypothesis are not corrected to avoid type 2 error.
MMPmatrix metalloproteinase; PCI percutaneous coronary int
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24 h after PCI.MMP-2 and -9 are produced by various cells like endothe-
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ead to basement membrane degradation that plays a key role
n liberating contractile vascular smooth muscle cells to partic-
pate in repair after arterial injury. MMP-2 and -9 are crucial
Restenosis
No Restenosis
(n  73) p Value
Corrected
p Value*
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95or migration of vascular smooth muscle cells and matrix remod-
ling during wound healing (18). MMP-inhibition studies in
nimal models showed significant reductions in pathological
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Figure 3. Restenosis Rates According to Quartiles of MMP Serum Activitie
Restenosis rates according to quartiles of matrix metalloproteinase (MMP)-2 ac
(B), MMP-9 activity before PCI (C), and MMP-9 activity after PCI (D).
Table 4. Logistic Regression Model Assessing the Ri
Drug-Eluting Stents
MMP-2 activity after PCI
MMP-9 activity baseline
MMP-9 activity after PCI
Adjusted for patient characteristics
MMP-2 activity after PCI adjusted for hypertension*
MMP-9 activity baseline adjusted for HDL*
MMP-9 activity after PCI adjusted for BMI*
Adjusted for angiographic and procedural characteristics
MMP-2 activity after PCI adjusted for stent diameter†
MMP-9 activity baseline adjusted for type of stent†
MMP-9 activity after PCI adjusted for type of stent†
*Strongestconfoundingvariable,ofhypertension,bodymass index(BMI),
†Strongest confounding variable, of vessel size, type of lesion, stent diamMMPmatrix metalloproteinase; PCI percutaneous coronary interventioemodeling (19–21). Although effects of MMP-inhibitors on
he final intimal size are controversial (22–24), research on
MP-inhibitors as stent-coating material is ongoing (25).
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1.17 1.08–1.27 0.0002
1.07 1.01–1.13 0.024
1.11 1.04–1.19 0.001
1.17 1.08–1.27 0.0002
1.07 1.01–1.12 0.023
1.11 1.04–1.18 0.001
nsity lipoproteincholesterol (HDL),diabetes,andC-reactiveprotein(CRP).
e of stent, number of stents, and total segment length.B
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MMP-2 and -9 Predict In-Stent Restenosis
96In our study, the post-procedural activities of MMP-2
nd -9 activity were correlated with angiographic late
umen loss. Surprisingly, despite the strong evidence that
echanical injury (3–7) and contact of peripheral blood
onocytes with activated endothelial cells (26) rapidly increases
elatinase activity (3,8), patients who were free of ISR at
ollow-up angiography showed no or only minimal increases in
erum activity of MMP-2 and -9 24 h after PCI. In contrast,
atients with future ISR showed a significant increase in
MP-2 and -9 serum activity after the procedure.
Similar results were obtained for patients with PES and
ES. The MMP-9 activity after PCI showed a strong corre-
ation with late lumen loss of both stent types. The MMP-2
ctivity significantly correlated with late lumen loss of PES and
howed only a trend to correlate with late lumen loss of SES.
owever, this might be explained by the smaller number and
ower restenosis rate of SES in our study.
The PCI-induced increase of MMP-2 activity was asso-
Figure 4. Correlation of MMP Serum Activities and Angiographic Late Lum
Correlation of serum activity of matrix metalloproteinase (MMP)-2 and -9 with
stents (B, E), and patients with sirolimus-eluting stents (C, F). In patients with
loss is included.iated with an increase of MMP-2 total antigen that was sompletely absent in patients without future ISR. In con-
rast, baseline levels of total antigen and the PCI-induced
elease of MMP-9 antigen was not different in both groups,
uggesting an increased activation of pro–MMP-9 to its
ctive form due to cleavage by plasmin and other MMPs in
atients with future ISR.
Multiple logistic regression analysis showed that
MP-9 activity at baseline and MMP-2 and -9 activity
fter PCI predicted the occurrence of restenosis after
mplantation of DES independently of clinical risk factors as
ell as angiographic and procedural characteristics. We also
ncluded the acute phase protein C-reactive protein in the
odel and could demonstrate that the predictive value of
MP-2 and -9 was independent of this unspecific inflamma-
ory marker.
In contrast to MMP-9 activity at baseline, MMP-2 activity
efore PCI did not predict the occurrence of ISR. In addition,
MP-2 and -9 activity before the intervention were not
s
graphic late lumen loss of all patients (A, D), patients with paclitaxel-eluting
le lesion interventions (n  45), only the lesion with the highest late lumenen Los
angio
multipignificantly associated with the grade of intimal hyperplasia.
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97owever, post-procedural levels of MMPs might be useful for
isk stratification, because patients with an increase of MMPs
nd a very high risk of restenosis could be monitored more
losely (e.g., with stress test or re-angiography).
tudy limitations. Some limitations of the present study have
o be acknowledged. Because the primary end point of this
tudy was angiographic restenosis, we included only patients
ho gave their informed consent for control angiography.
owever, we do not believe that selection bias plays a major
ole, because these patients did not differ with respect to
aseline characteristics and outcome from the total cohort of
atients who had PCI with implantation of DES. Further-
ore, our study is necessarily of an observational nature.
ccordingly, our results might be explained by unmeasured
onfounding factors. Therefore, we tried to control for baseline
mbalances by multivariate modeling. The possibility of resid-
al or undetected confounding is small but cannot be ruled out
ompletely. Although the predictive value of MMP-2 and -9
as highly significant, this study was not powered for calcula-
ion of clinical cutoff values, due to the relatively low number of
atients who develop ISR after implantation of DES. This
eeds to be further evaluated in larger, multicenter trials.
onclusions
his study provides evidence that serum activity of MMP-2
nd -9 might play a role in the pathogenesis of ISR after
mplantation of DES. An elevated baseline activity of MMP-9
nd increased levels of MMP-2 and -9 activity after PCI with
mplantation of DES are associated with restenosis rates of
8.9% to 42.9%. In real world populations, ISR still plays a
ignificant role after implantation of DES. Therefore, deter-
ination of MMP-2 and -9 activity might identify patients
ho are particularly at high risk for development of ISR.
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